Evaluation of Efficacy and Safety of Obinutuzumab Preemptive Treatment at the Time of the Molecular Relapse After First Line Immunochemotherapy With Autologous Stem Cell (ML29157).
Phase of Trial: Phase II
Latest Information Update: 24 Oct 2018
At a glance
- Drugs Obinutuzumab (Primary)
- Indications Mantle-cell lymphoma
- Focus Therapeutic Use
- Acronyms OPERA PLRG-10
- 15 Oct 2018 Status changed from not yet recruiting to recruiting.
- 28 Jul 2017 New trial record